April 2003
Worldwide Biotech;Apr2003, Vol. 15 Issue 4, p8
Trade Publication
Reports on the clinical collaboration between Immunicon Corp. and Igeneon to expand indications for use of diagnostic tests of Immunicon, as of April 2003.


Related Articles

  • Immunicon Files for Bankruptcy.  // Bioworld Week;6/16/2008, Vol. 16 Issue 24, p5 

    The article reports on the Chapter 11 bankruptcy filed by Immunicon Corp., a company based in Huntingdon Valley, Pennsylvania. As the result of bankruptcy, the company agreed to sell all assets to its partner Veridex LLC, for $31 million in cash. The proceeds from the sale would be used first to...

  • Immunicon gets funds to develop new acute myloid leukemia test.  // Diagnostics & Imaging Week;5/1/2008, Vol. 11 Issue 18, p7 

    The article reports on a grant received by Immunicon from the Center for Translational Molecular Medicine. The grant will be used for the development of a test that will detect minimal residual disease in blood and acute myeloid leukemia patients. The program, set to launch in September 2008, is...

  • Market watch. Macilwain, Colin // Nature;6/29/2006, Vol. 441 Issue 7097, p1047 

    The article focuses on the performance of stocks of nanotechnology companies in the U.S. as of June 2006. The steep drop in the index is not much different from that in the Nasdaq. However, some stocks still managed to do well. Nanocrystal spray-on bandages manufacturer Nucryst Pharmaceuticals...

  • Immunicon devices get boost via data presented at SABCS. Pedersen, Amanda // Medical Device Daily;12/14/2007, Vol. 11 Issue 227, p1 

    The article reports on the studies presented during the San Antonio Breast Cancer Symposium at the Henry B. Gonzalez Convention Center in Texas. Several studies feature the CellTracks technology and CellSearch Circulating Tumor Cell (CTC) kit of Immunicon. The studies showed that CTC is strong...

  • New Technologies Aim To Find Cancer in the Blood. Beckman, Mary // JNCI: Journal of the National Cancer Institute;9/6/2006, Vol. 98 Issue 17, p1180 

    The article focuses on technologies that can be used in characterizing the rare cancer cells known as circulating tumor cells (CTC). One is Immunicon's CellSearch. It is the best known CTC detection method, which identifies cancer cells in the blood by using antibodies directed against an...

  • Cell Culture Focus.  // Bioscience Technology;Feb2007, Vol. 32 Issue 2, p32 

    The article evaluates several products related to cell culture including EasyCount System fluorescent microscopy-based imaging system from Immunicon Corp., Cell Culture Flasks from NUNC and ColliGen 310 bioreactor from New Brunswick Scientific Co., Inc.

  • Financings roundup.  // Diagnostics & Imaging Week;8/30/2007, Vol. 10 Issue 35, p8 

    The article reports on a universal shelf registration statement filed by Immunicon with the Securities and Exchange Commission to allow the company to sell up to $75 million of its stocks. Immunicon plans to offer its common stock, preferred stock, debt securities, warrants, depositary shares,...

  • Veridex Buys Bankrupt Partner. Ruth, JaĆ£o-Pierre // njbiz;6/16/2008, Vol. 21 Issue 25, p2 

    The article reports on the decision of Veridex to purchase the assets of bankrupt Immunicon Corp. It notes that the firms have partnered since 2000 developing cancer diagnostic products. It cites that Immunicon decided to file for Chapter 11 bankruptcy protection the same day it agreed to be...

  • Immunicon in bankruptcy, will sell assets to Veridex.  // Diagnostics & Imaging Week;6/19/2008, Vol. 11 Issue 25, p3 

    The article reports on Chapter 11 bankruptcy protection that was filed by Huntingdon Valley, Pennsylvania-based Immunicon. It also agreed to sell its assets to Raritan, New Jersey-based Veridex. The total amount generated by Immunicon from selling its assets was $31 million. Based on the...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics